Abstract
In late 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China and quickly spread into a worldwide pandemic. It has caused millions of hospitalizations and deaths, despite the use of COVID-19 vaccines. Convalescent plasma and monoclonal antibodies emerged as major therapeutic options for treatment of COVID-19. We have developed an anti-SARS-CoV-2 immunoglobulin intravenous (Human) (COVID-HIGIV), a potential improvement from using convalescent plasma. In this report the efficacy of COVID-HIGIV was evaluated in hamster and mouse models of SARS-CoV-2 infection. COVID-HIGIV treatment in both mice and hamsters significantly reduced the viral load in the lungs. Among COVID-HIGIV treated animals, infection-related body weight loss was reduced and the animals regained their baseline body weight faster than the PBS controls. In hamsters, COVID-HIGIV treatment reduced infection-associated lung pathology including lung inflammation, and pneumocyte hypertrophy in the lungs. These results support ongoing trials for outpatient treatment with COVID-HIGIV for safety and efficacy evaluation ( NCT04910269 , NCT04546581 ).
【초록키워드】 COVID-19, Treatment, convalescent plasma, SARS-CoV-2, Efficacy, coronavirus, Hospitalization, hamsters, SARS-COV-2 infection, monoclonal antibody, Human, virus, anti-SARS-CoV-2, Spread, China, COVID-19 vaccines, Immunoglobulin, Viral load, mice, Lungs, plasma, hamster, mouse model, Lung pathology, Lung inflammation, deaths, therapeutic option, intravenous, Support, acute respiratory syndrome, worldwide pandemic, Body weight loss, controls, caused, significantly, evaluated, reduced, treated, faster, PBS, was reduced, baseline, ongoing trial, 【제목키워드】 SARS-COV-2 infection, animal model,